# Gelsectan® in the Treatment of Patients With Diarrhoea-predominant Irritable Bowel Syndrome

> **NCT06681012** · NA · RECRUITING · sponsor: **Devintec Sagl** · enrollment: 330 (estimated)

## Conditions studied

- Irritable Bowel Syndrome (IBS)
- Irritable Bowel Syndrome of Diarrhea Type (IBS-D)

## Interventions

- **DEVICE:** Gelsectan®
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06681012
- **Lead sponsor:** Devintec Sagl
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-22
- **Primary completion:** 2027-07
- **Final completion:** 2027-07
- **Target enrollment:** 330 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06681012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06681012, "Gelsectan® in the Treatment of Patients With Diarrhoea-predominant Irritable Bowel Syndrome". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT06681012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*